AstraZeneca Acquires Modella AI

AstraZeneca Acquires Fusion Pharmaceuticals

March 19, 2024

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.

AstraZeneca (Alexion) to Acquire Amolyt Pharma for up to $1.05B

March 14, 2024

Biotechnology

AstraZeneca, via its Alexion Rare Disease business, has agreed to acquire clinical-stage biotechnology company Amolyt Pharma for $800 million upfront plus up to $250 million in milestone payments (total consideration up to $1.05 billion). Amolyt, based in Lyon, France (with a presence in Boston, US), is developing peptide therapeutics for rare endocrine diseases including lead asset eneboparatide (AZP-3601), currently in Phase 3; the deal is expected to close in 3Q 2024 subject to customary conditions.

Aktana Acquires Ople.AI's Machine Learning Automation Technology

October 27, 2021

AI & Machine Learning

Aktana has acquired Ople.AI's machine learning automation technology to integrate into its Contextual Intelligence 360 platform, enabling non-data scientists at life sciences companies to build and deploy ML models more easily. The acquisition is intended to democratize AI across commercial life sciences teams and accelerate AI adoption by simplifying model creation, deployment and transparent explanations.

ZS Acquires Trials.ai to Add AI-Driven Study Design

February 6, 2023

AI & Machine Learning

Global consulting and technology firm ZS has entered into a definitive agreement to acquire Trials.ai, an AI-powered clinical study design company. The acquisition will integrate Trials.ai's intelligent study-design capabilities into ZS's clinical development offerings to help sponsors identify risks, optimize participant experience and accelerate therapy development timelines.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.

BioCryst Pharmaceuticals Acquires Astria Therapeutics

January 26, 2026

Biotechnology

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics for an implied transaction value of approximately $700 million, financed with cash on hand and a ~$396.6 million facility provided by funds managed by Blackstone plus ~37.3 million BioCryst shares issued to Astria equity holders. The deal adds Astria's Phase 3 long-acting plasma kallikrein inhibitor navenibart to BioCryst's hereditary angioedema (HAE) portfolio and provides Astria's early-stage atopic dermatitis program (STAR0310) for which BioCryst will pursue strategic alternatives.